What it's for (Indications)
- Iron sucrose, an intravenous iron replacement product (e.
- g.
- , Venofer), is primarily indicated for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).
- This includes individuals who are on hemodialysis (HD) and receiving concomitant erythropoietin-stimulating agents (ESAs), as well as those who are not on dialysis (NDD-CKD) or on peritoneal dialysis (PD-CKD) and receiving ESAs.
- Furthermore, it is indicated for the treatment of IDA in adult patients with non-dialysis dependent CKD who are not receiving an ESA, particularly when oral iron supplementation is either ineffective or not tolerated due to adverse gastrointestinal effects.
- The objective of iron sucrose therapy is to replete body iron stores and increase hemoglobin levels, thereby alleviating symptoms associated with iron deficiency and optimizing the response to ESA therapy, if applicable.
- Careful diagnostic evaluation of iron deficiency is crucial before initiating treatment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Iron sucrose is administered intravenously, with dosing regimens varying based on the patient's specific CKD status and whether they are receiving dialysis. For adult hemodialysis-dependent (HDD-CKD) patients, the recommended cumulative dose is 1000 mg, typically administered as 100 mg slow intravenous injection or infusion during successive dialysis sessions, usually 3 times per week for a total of 10 doses. For adult non-dialysis-dependent (NDD-CKD) patients, a cumulative dose of 1000 mg can be given as 200 mg slow intravenous injection on 5 different occasions over a 14-day period, or as two 500 mg doses administered on consecutive days. Adult peritoneal dialysis-dependent (PDD-CKD) patients may receive a cumulative dose of 1000 mg, administered as 300 mg in two doses given 5 days apart, followed by a third dose of 400 mg after another 4 days, or as four doses of 100 mg administered over 2 weeks. The rate of infusion should be strictly adhered to, typically 100 mg diluted in a maximum of 100 mL 0.9% NaCl over 15 minutes, or larger doses diluted and infused over 30 to 60 minutes, to minimize the risk of hypotension and other infusion-related reactions. Patients should be monitored for signs of hypersensitivity during and after administration. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with iron sucrose administration include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain.
- Cardiovascular effects like hypotension, hypertension, and peripheral edema are also frequently reported.
- Other systemic reactions may include headache, dizziness, asthenia (weakness), malaise, pain in extremities, back pain, and arthralgia.
- Injection site reactions, such as pain, irritation, and discoloration from extravasation, can occur.
- More serious, though less frequent, adverse events include severe hypersensitivity reactions (e.
- g.
- , anaphylaxis, shock, bronchospasm, angioedema, urticaria, pruritus, rash), which can be life-threatening.
- Patients may also experience transient taste perversion, paresthesias, or fever.
- Careful monitoring during and after infusion is essential to promptly identify and manage any adverse effects, particularly hypersensitivity reactions and significant fluctuations in blood pressure.
- The risk of these adverse effects necessitates a thorough risk-benefit assessment for each patient.
Serious Warnings
- Black Box Warning: Iron sucrose (e.g., Venofer) does not carry a formal FDA Black Box Warning. However, it is imperative to highlight a critical safety concern regarding **Serious Warnings: Hypersensitivity Reactions (including Anaphylaxis)**. Intravenous iron products, including iron sucrose, have been associated with serious and potentially fatal hypersensitivity reactions. These reactions can manifest as anaphylactic shock, collapse, cardiopulmonary arrest, severe hypotension, bronchospasm, dyspnea, syncope, loss of consciousness, angioedema, urticaria, rash, and pruritus. The risk of such reactions is elevated in patients with a history of allergies, asthma, or other atopic conditions. Patients must be closely monitored for signs and symptoms of hypersensitivity during and for at least 30 minutes following each administration of iron sucrose. Emergency resuscitation equipment and personnel trained in recognizing and treating severe hypersensitivity reactions, including anaphylaxis, must be immediately available during therapy. If a hypersensitivity reaction occurs, the administration of iron sucrose must be immediately discontinued, and appropriate medical management should be initiated.
- Intravenous iron sucrose carries several significant warnings.
- The most critical concern is the risk of serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal.
- These reactions can occur even in patients who have previously tolerated iron sucrose.
- Therefore, resuscitation equipment and trained personnel must be immediately available during administration, and patients should be monitored for at least 30 minutes post-infusion.
- Hypotension, often dose-related and associated with too rapid administration, is another significant risk; blood pressure should be carefully monitored.
- Patients with a history of allergies, asthma, or other atopic conditions may be at increased risk for hypersensitivity reactions.
- Repeated administration of intravenous iron without adequate monitoring of iron parameters (e.
- g.
- , ferritin, transferrin saturation) can lead to iron overload, which may result in hemosiderosis.
- Extravasation at the injection site can cause persistent skin discoloration and irritation, necessitating careful venipuncture technique.
- Caution is advised in patients with active bacterial infections, as parenteral iron may exacerbate infection.
- The use of iron sucrose during pregnancy should be carefully considered, weighing the potential benefits against the risks, particularly during the first trimester.
How it Works (Mechanism of Action)
Iron sucrose is an aqueous complex of polynuclear iron(III)-hydroxide and sucrose, designed for intravenous administration to replenish iron stores. Upon intravenous infusion, the iron sucrose complex is thought to be rapidly taken up by the reticuloendothelial system, particularly macrophages, in the liver, spleen, and bone marrow. Within these cells, the iron is gradually released from the sucrose complex. This released iron then binds to transferrin, the primary iron-transport protein in the plasma, which subsequently delivers it to erythroid precursor cells in the bone marrow. Here, the iron is incorporated into heme, a crucial component of hemoglobin, facilitating the synthesis of new red blood cells (erythropoiesis). The sucrose component stabilizes the iron and ensures a controlled release, preventing the rapid release of free iron that could lead to toxicity. By directly providing bioavailable iron, iron sucrose bypasses potential absorption issues in the gastrointestinal tract, making it an effective treatment for iron deficiency anemia, especially in patients with chronic kidney disease who often have impaired iron absorption or increased iron requirements.